TITLE:
Adult Onset Still’s Disease
AUTHORS:
Madiha Mahfoudhi, Imen Gorsane, Rafik Shimi, Sami Turki, Taieb Ben Abdallah
KEYWORDS:
Adult Onset Still’s Disease, Cytokine, TNF Alpha Receptor Antagonist, Interleukin 6 Receptor Antagonist, Interleukin 1 Receptor Antagonist
JOURNAL NAME:
International Journal of Clinical Medicine,
Vol.6 No.10,
October
13,
2015
ABSTRACT: The adult onset Still’s disease is a rare affection characterised by occurrence of fever, arthralgia or arthritis and evanescent cutaneous eruption. Multiple other systemic lesions make the diagnosis more difficult. Several diagnostic criteria were formulated to confirm this disease. The physiopathology of the adult onset Still’s disease is not well elucidated. However, several studies based on new facts in physiopathology, improved the therapy of refractory forms for which the biotherapy was an interesting alternative. The TNF alpha receptor antagonists are efficient on systemic and articular manifestations of this disease and allow a corticosteroid’s saving. Tocilizumab (interleukin 6 receptor antagonist), and Anakinra (interleukin 1 receptor antagonist) are also new promising treatments for resistant forms.